 | | Vol. 15.42 – 26 October, 2023 |
| |
|
|
| Scientists showed that therapeutically targeting the RNA helicase eIF4A by Zotatifin exerted pleiotropic effects on both tumor cells and the tumor immune microenvironment in a diverse cohort of syngeneic TNBC mouse models.
[Journal Of Clinical Investigation] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Mechanistically, mutant p53, unlike the wild-type counterpart, induced the expression of serine-synthesis-pathway enzymes and L-type amino acid transporter 1/CD98 heavy chain heterodimer.
[Nature Communications] |
|
|
|
| To investigate the effect of adipocyte-Gremlin-2 on breast cancer cells, investigators analyzed the proliferative and invasion abilities of spheroids using a 3D co-culture system of breast cancer cells and adipocytes, or conditioned medium of adipocytes.
[Breast Cancer Research] |
|
|
|
| Researchers demonstrated in 3D cultures of patient-derived breast cancer explants that both basal TGFβ signaling and EGFR protein expression were inhibited by neutralizing antibodies or small-molecule inhibitors of hepsin.
[Molecular Oncology] |
|
|
|
| Scientists screened the US FDA-approved drug library and identified zinc pyrithione as a compound that significantly inhibited TNBC progression.
[iScience] |
|
|
|
| The authors discovered that the natural product Enniatin A targeted Hsp90 and destabilized its client oncoproteins without inducing a heat shock response.
[iScience] |
|
|
|
| The breast cancer cell line MDA-MB-231 was chosen as a model, and the photodynamic effect of Tanshinone I on cancer cells was evaluated by MTT assay and flow cytometry.
[Scientific Reports] |
|
|
|
| A murine xenograft model assay was performed to determine circ_0001982-induced effects on breast cancer cell tumor properties in vivo.
[Journal Of Biochemical And Molecular Toxicology] |
|
|
|
| Treatment with guanosine or guanine nucleotides increased mitochondrial production of reactive oxygen species, and modified the cell cycle.
[Biological & Pharmaceutical Bulletin] |
|
|
|
|
| Scientists review and discuss the latest knowledge about the salient attributes of metastasis and epigenetic regulation in breast cancer and crucial research domains that need further investigation.
[Cancer and Metastasis Reviews] |
|
|
|
|
| Bolt Biotherapeutics announced that the first patient has been dosed with BDC-3042 in the single-agent dose-escalation portion of this first-in-human Phase I/II clinical study. They evaluate BDC-3042 in patients with metastatic or unresectable cancers including triple-negative breast cancer, colorectal cancer, non-small cell lung cancer.
[Bolt Biotherapeutics] |
|
|
|
|
| December 2 – 6, 2023
Boston, Massachusetts, United States |
|
|
|
|
|
| | University of Pennsylvania – Philadelphia, Pennsylvania, United States |
|
|
|
| | University of Gothenburg – Gothenburg, Sweden |
|
|
|
| | University of Alabama at Birmingham – Birmingham, Alabama, United States |
|
|
|
| | Ume̴ University РUme̴, Sweden |
|
|
|
| | NYU Medical Center – New York, New York, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
